Sun Sep 15 12:40:53 UTC 2024: ## Jupiter Asset Management Invests in Merck & Co., Inc. Amidst Growing Institutional Interest
**New York, NY** – Jupiter Asset Management Ltd. has shown confidence in Merck & Co., Inc. (NYSE:MRK) by purchasing a new position in the healthcare giant during the second quarter, according to Holdings Channel. This investment, valued at approximately $375,000, reflects a growing trend of institutional investors showing interest in the company.
Other hedge funds have also adjusted their holdings in MRK, with several new positions established and some increasing their existing stakes. Notably, Roble Belko & Company Inc. boosted its holdings in MRK by 35.3% in the first quarter, demonstrating further confidence in the company’s future.
The move comes as Merck & Co., Inc. continues to deliver strong financial performance, with a robust dividend payout ratio of 342.22% and a recent announcement of a quarterly dividend of $0.77 per share.
Analysts remain optimistic about MRK’s prospects. Wolfe Research recently upgraded the company to a “strong-buy” rating, while Cantor Fitzgerald reiterated an “overweight” rating. Overall, the consensus rating for the stock is “Buy” with a price target of $134.58.
Merck & Co., Inc.’s stock has a market cap of $293.45 billion and operates in two segments: Pharmaceutical and Animal Health. The company is known for its diverse portfolio of products, including Keytruda, Simponi, and Gardasil vaccines.
With several institutional investors increasing their stake in the company, Merck & Co., Inc. appears well-positioned for continued growth. This latest investment by Jupiter Asset Management highlights the increasing confidence in the pharmaceutical giant’s future prospects.
First Piper 